van de Donk NWCJ, Zweegman S. T-cell-engaging bispecific antibodies in cancer. Lancet. 2023;402(10396):142–58.

Article  PubMed  Google Scholar 

Wang Q, Chen Y, Park J, et al. Design and production of bispecific antibodies. Antibodies (Basel). 2019;8(3):43.

Article  PubMed  PubMed Central  Google Scholar 

Wei J, Yang Y, Wang G, Liu M. Current landscape and future directions of bispecific antibodies in cancer immunotherapy. Front Immunol. 2022;13:1035276.

Article  CAS  PubMed  PubMed Central  Google Scholar 

US FDA. BLA accelerated approval (elranatamab-bcmm). 2023. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/761345Orig1s000ltr.pdf. Accessed 28 Aug 2023.

Pfizer Inc. ELREXFIOTM (elranatamab-bcmm): US prescribing information. 2023. https://labeling.pfizer.com/ShowLabeling.aspx?id=19669. Accessed 28 Aug 2023.

European Medicines Agency. CHMP summary of positive opinion for Elrexfio (elranatamab). 2023. https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-elrexfio_en.pdf. Accessed 18 Oct 2023.

Bahlis NJ, Costello CL, Raje NS, et al. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med. 2023. https://doi.org/10.1038/s41591-023-02589-w.

Article  PubMed  PubMed Central  Google Scholar 

Dalovisio A, Bahlis N, Raje N, et al. Updated results from the ongoing phase 1 study of elranatamab, a BCMA targered T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma [abstract no. P897]. HemaSphere. 2022;6(S3):1509–10.

Raje N, Bahlis NJ, Costello C, et al. Elranatamab, a BCMA targeted T-cell engaging bspecific antibody, induces durable clinical and molecular responses for patients with relapsed or refractory multiple myeloma [abstract]. Blood. 2022;140(Suppl 1):388–90.

Article  Google Scholar 

Rodriguez-Otero P, Quach H, Weisel K, et al. Genomic analysis to identify determinants of inherent response and resistance to elranatamab in MagnetisMM-3 cohort A [abstract no. P906]. HemaSphere. 2023;7(S3):1709–10.

Elmeliegy M, Viqueira A, Vandendries E, et al. Dose optimization to mitigate the risk of CRS with elranatamab in multiple myeloma [abstract]. Blood. 2022;140(Supplement 1):7174–5.

Article  Google Scholar 

Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023. https://doi.org/10.1038/s41591-023-02528-9.

Article  PubMed  PubMed Central  Google Scholar 

Manier S, Lesokhin A, Mohty M, et al. Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma and prior B-cell maturation antigen (BCMA)-directed therapies: a pooled analysis from MagnetisMM studies [abstract no. P870 plus poster]. HemaSphere. 2023;7(S3):1633–34.

Leleu X, Iida S, Landgren CO, et al. Elranatamab monotherapy or in combination with daratumumab vs daratumumab + pomalidomide + dexamethasone for patients with relapsed/refractory multiple myeloma: phase 3 MagnetisMM-5 Study, Part 2 [abstract no. P930]. HemaSphere. 2023;7(S3):1758.

Manteca MVM, Grosicki S, Kim K. Magnetismm-7: an open-label, multicenter, randomized phase 3 study of elranatamab versus lenalidomide in post-transplant patients with newly dagnosed multiple myeloma [abstract no. PB2131]. HemaSphere. 2023;7(S3):4084.

Manteca MVM, Grosicki S, Kim K. MagnetisMM-7: an open-label, multicenter, randomized phase 3 study of elranatamab versus lenalidomide in post-transplant patients with newly diagnosed multiple myeloma [abstract no. TPS8066]. J Clin Oncol. 2023;41(16 Suppl).

Landgren O, Kazandjian D, O’Connell A, et al. Magnetismm-4: an open label, phase 1b/2 umbrella study of elranatamab in combination with other anti-cancer treatments for patients with multiple myeloma. Blood. 2022;140(Suppl 1):10172–3.

Article  Google Scholar 

Fonseca R, Kuroda J, Ishida T, et al. MagnetisMM-9: an open-label, multicenter, non-randomized phase 1/2 study of elranatamab in patients with relapsed/refractory multiple myeloma [abstract no. TPS8068]. J Clin Oncol. 2022;40(16 Suppl).

Fonseca R, Kuroda J, Ishida T, et al. MafnetisMM-9: an open-label, multicenter, non-randomized phase 1/2 study of elranatamab in patients with relapsed/refractory multiple myeloma [abstract no. PB2032]. HemaSphere. 2022;6(S3):3518.